PDCD1 and colorectal carcinoma: The first type of immunotherapy agent licensed for CRC are three different antibodies (Pembrolizumab from Merck, Dorstalimab from Glaxo Smith Klein and Nivolumab from Bristol Meyers Squibb) that act by blocking the programmed cell death protein 1 (PD1) immune checkpoint.